312 related articles for article (PubMed ID: 26462154)
41. Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations.
Scholl S; Melle C; Bleul A; Spies-Weisshart B; Kunert C; Höffken K; von Eggeling F
Leuk Lymphoma; 2007 Dec; 48(12):2418-23. PubMed ID: 18067018
[TBL] [Abstract][Full Text] [Related]
42. "Cup-like" blasts and NPM1 and FLT3 (ITD) mutations in acute myeloid leukemia (AML).
Jain P; Vega-Vazquez F; Faderl S
Int J Hematol; 2013 Jul; 98(1):3. PubMed ID: 23690292
[No Abstract] [Full Text] [Related]
43. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation.
Ortlepp C; Steudel C; Heiderich C; Koch S; Jacobi A; Ryser M; Brenner S; Bornhäuser M; Brors B; Hofmann WK; Ehninger G; Thiede C
Exp Hematol; 2013 May; 41(5):444-461.e4. PubMed ID: 23377000
[TBL] [Abstract][Full Text] [Related]
44. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
[TBL] [Abstract][Full Text] [Related]
45. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
Reiter K; Polzer H; Krupka C; Maiser A; Vick B; Rothenberg-Thurley M; Metzeler KH; Dörfel D; Salih HR; Jung G; Nößner E; Jeremias I; Hiddemann W; Leonhardt H; Spiekermann K; Subklewe M; Greif PA
Leukemia; 2018 Feb; 32(2):313-322. PubMed ID: 28895560
[TBL] [Abstract][Full Text] [Related]
46. [FLT3 mutations in children with acute myeloid leukemia: a single center study].
Ruan M; Wang YQ; Zhang L; Liu TF; Liu F; Liu XM; Zhang JY; Zou Y; Chen YM; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov; 13(11):863-6. PubMed ID: 22099191
[TBL] [Abstract][Full Text] [Related]
47. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
[TBL] [Abstract][Full Text] [Related]
48. Wilms' tumor protein and FLT3-internal tandem duplication expression in patients with de novo acute myeloid leukemia.
Spassov BV; Stoimenov AS; Balatzenko GN; Genova ML; Peichev DB; Konstantinov SM
Hematology; 2011 Jan; 16(1):37-42. PubMed ID: 21269566
[TBL] [Abstract][Full Text] [Related]
49. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
[TBL] [Abstract][Full Text] [Related]
50. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
51. Cytarabine-Resistant
Ko YC; Hu CY; Liu ZH; Tien HF; Ou DL; Chien HF; Lin LI
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862120
[TBL] [Abstract][Full Text] [Related]
52. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
53. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.
Sun YM; Wang WT; Zeng ZC; Chen TQ; Han C; Pan Q; Huang W; Fang K; Sun LY; Zhou YF; Luo XQ; Luo C; Du X; Chen YQ
Blood; 2019 Oct; 134(18):1533-1546. PubMed ID: 31387917
[TBL] [Abstract][Full Text] [Related]
54. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
55. DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.
Wu M; Hamaker M; Li L; Small D; Duffield AS
Leukemia; 2017 Mar; 31(3):688-696. PubMed ID: 27748370
[TBL] [Abstract][Full Text] [Related]
56. [Correlation of Fms-like tyrosine kinase 3 (FLT3) gene expression to FLT3/internal tandem duplication mutation in peripheral blood of acute myeloid leukemia.].
Xu B; Shi PC; Song XY; Tang JH; Zhou SY
Ai Zheng; 2009 Jun; 28(6):632-6. PubMed ID: 19635202
[TBL] [Abstract][Full Text] [Related]
57. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
[TBL] [Abstract][Full Text] [Related]
58. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
Nordigården A; Zetterblad J; Trinks C; Gréen H; Eliasson P; Druid P; Lotfi K; Rönnstrand L; Walz TM; Jönsson JI
Br J Haematol; 2011 Oct; 155(2):198-208. PubMed ID: 21848891
[TBL] [Abstract][Full Text] [Related]
59. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
Akiyama H; Umezawa Y; Ishida S; Okada K; Nogami A; Miura O
Cancer Lett; 2019 Jul; 453():84-94. PubMed ID: 30946869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]